Olema Pharmaceuticals Inc
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen rec… Read more
Olema Pharmaceuticals Inc (OLMA) - Total Assets
Latest total assets as of September 2025: $352.45 Million USD
Based on the latest financial reports, Olema Pharmaceuticals Inc (OLMA) holds total assets worth $352.45 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Olema Pharmaceuticals Inc - Total Assets Trend (2018–2024)
This chart illustrates how Olema Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Olema Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Olema Pharmaceuticals Inc's total assets of $352.45 Million consist of 97.2% current assets and 2.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 30.9% |
| Accounts Receivable | $2.12 Million | 0.5% |
| Inventory | $-4.02 Million | -0.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $683.00K | 0.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Olema Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Olema Pharmaceuticals Inc's current assets represent 97.2% of total assets in 2024, a decrease from 99.1% in 2018.
- Cash Position: Cash and equivalents constituted 30.9% of total assets in 2024, down from 96.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
Olema Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Olema Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Olema Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Olema Pharmaceuticals Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Olema Pharmaceuticals Inc is currently not profitable relative to its asset base.
Olema Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.03 | 7.10 | 74.62 |
| Quick Ratio | 8.03 | 7.10 | 74.62 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $292.67 Million | $ 187.29 Million | $ 337.55 Million |
Olema Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Olema Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.62 |
| Latest Market Cap to Assets Ratio | 1.79 |
| Asset Growth Rate (YoY) | 62.8% |
| Total Assets | $450.98 Million |
| Market Capitalization | $805.92 Million USD |
Valuation Analysis
Above Book Valuation: The market values Olema Pharmaceuticals Inc's assets above their book value (1.79 x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Olema Pharmaceuticals Inc's assets grew by 62.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Olema Pharmaceuticals Inc (2018–2024)
The table below shows the annual total assets of Olema Pharmaceuticals Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $450.98 Million | +62.84% |
| 2023-12-31 | $276.94 Million | +28.43% |
| 2022-12-31 | $215.65 Million | -27.13% |
| 2021-12-31 | $295.94 Million | -13.65% |
| 2020-12-31 | $342.72 Million | +259537.88% |
| 2019-12-31 | $132.00K | -95.96% |
| 2018-12-31 | $3.27 Million | -- |